🚀 Pharmidex at BioWednesday Stevenage: Key Messages and Sentiments from JPM Week 2025 🚀
February 5, 2025
We are excited to share that our Business Development Manager, Janette Dalay Robertson, and Head of Operations,
Ash Alavijeh, had the pleasure of attending the BioWednesday Stevenage: Key Messages and Sentiments from JPM Week 2025 event today at the
Stevenage Bioscience Catalyst.
It was a fantastic opportunity to connect with industry leaders, potential clients, and partners. Janette and Ash were thrilled to engage in meaningful conversations, exploring new collaborations, and discussing the latest insights from JPM Week 2025.
At Pharmidex, we're committed to expanding our relationships and helping our clients navigate their path to success in drug discovery and development. Together, we’re working towards creating a healthier future.
A big thank you to everyone we had the pleasure of meeting today. We look forward to the continued conversations and collaborations!
#Pharmidex #BioWednesday #JPMWeek2025 #DrugDiscovery #Biotech #Innovation #Pharmaceuticals #Networking #StevenageBioScienceCatalyst
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
